-- Agreement with Health House for supply of Satipharm CBD Gelpell(R) 
Capsules throughout Australia, New Zealand and Asia 

Harvest One Cannabis Inc. ("Harvest One" or the "Company") (TSXV: HVT; OTCQX: 
HRVOF), through it's wholly-owned subsidiary Satipharm Ltd. ("Satipharm") today 
announced that it has entered into an agreement to become a supplier to the 
renowned medicinal cannabis wholesale & distribution business, Health House 
International Pty Ltd ("Health House"). 

Logo - https://mma.prnewswire.com/media/845924/Harvest_One_Cannabis_Inc_logo.jpg

Under the terms of the agreement, Harvest One will supply Health House with 
Satipharm CBD 50mg Gelpell(R) capsules ( 
https://c212.net/c/link/?t=0&l=en&o=2423165-1&h=2649485464&u=https%3A%2F%2Fsatipharm.com%2Fpages%2Fcbd-and-epilepsy&a=Satipharm+CBD+50mg+Gelpell%C2%AE+capsules 
) . The product will continue its availability in Australia, while expanding 
distribution to New Zealand and Asia where and when legal.

Under the agreement, Health House will purchase in bulk and distribute 
Satipharm's ( 
https://c212.net/c/link/?t=0&l=en&o=2423165-1&h=209340586&u=https%3A%2F%2Fsatipharm.com%2F&a=Satipharm 
) medicinal cannabis products to their existing network of pharmacies while 
also supporting healthcare professionals with Satipharm product information. 
Health House International are one of the major wholesalers to Australian 
pharmacies for medicinal cannabis. In May 2017 they imported one of the first 
legal international medicinal cannabis shipments into Australia. 

Satipharm CEO Jonathan Hartshorn commented: "This agreement with Health House 
increases the availability of our Satipharm CBD 50mg Gelpell(R) capsules across 
Australia, while expanding Satipharm's medical cannabis distribution 
territories to New Zealand and Asia. We are committed to delivering the highest 
quality cannabinoid-based products globally. As further regions become 
available, we will continue to put agreements in place that will allow us to 
meet the needs of our patients."

Pharmacist, CEO and founder of Health House Paul Mavor said: "The addition of 
Satipharm's 50mg Gelpell(R) capsules to our range allows us to provide 
clinically proven, high quality CBD to customers. The capsule is a 
pharmaceutically elegant and convenient dosage form for those who have been 
prescribed CBD."

About Satipharm

Satipharm is a health and wellness company which is specialised in the 
development and manufacture of cannabinoid-based products from the cannabis 
plant. Our mission is to deliver the highest quality products that are designed 
specifically with the needs of our customers in mind. 
 
About Health House

Health House International was the first medical cannabis importer into 
Australia and currently wholesales to pharmacies and researchers around the 
country. They have a team of pharmacists that can counsel prescribers on 
strengths, dosage, side effects and interactions. They offer a next business 
day delivery service for their range of medical cannabis products for 
authorised patients.

ABOUT HARVEST ONE CANNABIS INC.

Harvest One is a global cannabis company that develops and provides innovative 
lifestyle and wellness products to consumers and patients in regulated markets 
around the world. The Company's range of lifestyle solutions is designed to 
enhance quality of life. Shareholders have significant exposure to the entire 
cannabis value chain through three wholly-owned subsidiaries: United 
Greeneries, a Licensed Producer; Satipharm (medical and nutraceutical); and 
Dream Water Global (consumer), and a minority interest in Burb Cannabis (retail 
operations). For more information, please visit www.harvestone.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking 
information. These statements relate to future events or future performance. 
The use of any of the words "could", "intend", "expect", "believe", "will", 
"projected", "estimated" and similar expressions and statements relating to 
matters that are not historical facts are intended to identify forward-looking 
information and are based on the Company's current belief or assumptions as to 
the outcome and timing of such future events. Actual future results may differ 
materially. The forward-looking information contained in this press release is 
made as of the date hereof, and the Company is not obligated to update or 
revise any forward-looking information, whether as a result of new information, 
future events or otherwise, except as required by applicable securities laws. 
Because of the risks, uncertainties and assumptions contained herein, investors 
should not place undue reliance on forward-looking information. The foregoing 
statements expressly qualify any forward-looking information contained herein.

Neither TSX-V nor its Regulation Services Provider (as that term is defined in 
the policies of the TSX-V) accept responsibility for the adequacy or accuracy 
of this release.

Source - Harvest One Cannabis Inc.

CONTACT: Colin Clancy, Investor Relations, cclancy@harvestone.com, 
1-877-915-7934